A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
about
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsAntiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsCytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy?Psychotic symptoms and confusion associated with intravenous ganciclovir in a heart transplant recipientValganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacyCardiac transplantation: a review for critical care nurses.New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipientsPrevention of cytomegalovirus disease in recipients of solid-organ transplants.Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation.Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assaysA prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipientsCytomegalovirus infection after intestinal transplantation in childrenMacrophage activation associated with chronic murine cytomegalovirus infection results in more severe experimental choroidal neovascularization.Management of cytomegalovirus infection and disease after solid-organ transplantation.Prevention of infections in solid organ transplant recipients.Cytomegalovirus infection and cardiac allograft vasculopathy.Prevention and treatment of cytomegalovirus infection in organ transplant recipients.Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center.Cytomegalovirus treatment options in immunocompromised patients.Human cytomegalovirus-encoded pUL7 is a novel CEACAM1-like molecule responsible for promotion of angiogenesisCytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants.Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.Human cytomegalovirus terminase as a target for antiviral chemotherapy.The role of cytomegalovirus in angiogenesis.Role of cytomegalovirus in cardiac allograft vasculopathy.Cytomegalovirus seropositivity is associated with increased arterial stiffness in patients with chronic kidney disease.Beta-herpesvirus challenges in the transplant recipient.The economic value of valacyclovir prophylaxis in transplantation.Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3.Infections in solid-organ transplant recipientsAcyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis.Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies.Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxisHigh T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage.Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naïve recipientsInfection of vascular endothelial cells with human cytomegalovirus under fluid shear stress reveals preferential entry and spread of virus in flow conditions simulating atheroprone regions of the artery.Acceleration of allograft failure by cytomegalovirusHuman cytomegalovirus secretome contains factors that induce angiogenesis and wound healing.
P2860
Q24200697-A49236B2-5E7A-4588-9BDB-E1B304EFDF9CQ24200991-F39E16D5-3AB0-4227-ADF1-E7C557A93B8AQ24243124-DE07F31E-D8D6-4094-9A7B-D883879D1717Q24244606-C4081EB6-B7DE-49FA-A2AD-803DA24C83D1Q28082017-C236C8DD-91BF-4421-B0FA-D3C9D149AD6BQ28377161-E0001448-77D3-4B3B-B036-89ECE585EB3FQ28475480-A47BDE88-AE69-418F-A2F2-FD344F2F45D5Q33560856-D31EFE0E-6DE1-499C-96AE-96EACAA42598Q33812425-FFDC9FF7-7C21-4445-9098-C0FDA74301ADQ34142019-68802C87-88AE-47E9-95D6-52604DB1BD3BQ34191791-2C2FB96D-53B6-478B-A456-BBCFE452BE5CQ34202805-FDA7ECEC-885E-43D2-B1CE-7DC6AECB38A8Q34219755-064B07DA-A290-4D9B-B96B-DBC2503DBE55Q34232361-8A8101E6-3F78-4B2B-B234-1FC3C60CF886Q34263026-EACC5B49-078F-4CC7-9C44-982378AD95D0Q34271684-442FBCAF-A1CD-402F-A16E-D4B00F26A355Q34294796-C899A6A8-E808-41ED-9FCE-4033917CD28FQ34294809-7E04E58D-FD97-4003-99D7-28FF387EEEC3Q34294851-BCFD1BD8-0F26-4EA3-ABE8-6125DDD0823AQ34326446-79F341C9-344F-4A4A-AE79-C0951E6B348FQ34390197-B60A0922-8308-4075-8A37-B6102C470262Q34440895-0B8FDD29-2E31-4DF4-B4B1-9E156AF2C86FQ34467148-6E42A0D2-5D60-400A-85E6-325453D40CCAQ34481742-EB9718EB-F0DC-417C-9698-1BB80B010EB0Q34580776-367CF157-1256-4400-8E43-F5C9BD073E8DQ34581563-3AFEFFC9-D67E-40E5-9BAD-8C3BAD812D82Q34583505-D6B2F60A-620D-4ADB-8D11-38A1557D110EQ34602254-5677763D-D421-4426-AA5A-BB206C12CCE6Q34918418-C99E1154-7C52-4270-A837-5BD476A4AD49Q34918444-8D927967-B8E2-4B19-A05C-E1C0B2AE0A0CQ35116723-ABDF26C1-DEA9-4EC1-8704-DF2D16A16BC7Q35376486-FC60A47C-0F4B-468A-9DDA-768823CEFC4DQ35809290-E32C70D6-F689-461B-A782-39B4C2C9ED9EQ35900369-F931B192-3953-451B-BFFA-46706BDB3DBCQ35914030-4921F054-B5EB-4DDF-8F67-A91671BBE17AQ35990663-A7FA23BB-11AA-41AF-9921-1EC7C1012BABQ36266751-F23F9F06-55E5-43FA-908C-59B50B84901EQ36414448-F6FD9081-D2A5-4EF1-BF28-CAB7B735B21AQ36433529-F526C2DF-A1E7-4D66-99E0-41A27FF4BDD8Q36747994-FC11DBFF-6D7C-4F0D-9676-F2AE2A2EC13A
P2860
A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
A controlled trial of ganciclo ...... e after heart transplantation.
@en
type
label
A controlled trial of ganciclo ...... e after heart transplantation.
@en
prefLabel
A controlled trial of ganciclo ...... e after heart transplantation.
@en
P2093
P1476
A controlled trial of ganciclo ...... e after heart transplantation.
@en
P2093
Bristow MR
Merigan TC
O'Connell JB
Ratkovec RM
Renlund DG
P304
P356
10.1056/NEJM199204303261803
P407
P577
1992-04-01T00:00:00Z